Around 13% of South Africa’s population are living with HIV and the country has the world’s largest HIV treatment programme. The country’s finances are however under huge pressure and significant cuts were recently announced to government’s HIV budget. Catherine Tomlinson unpacks what a new HIV Investment Case can tell us about the possible paths forward.
Researchers have been trying to develop antiretroviral medicines that can last for weeks, months or even years per dose. Two such long-acting formulations have been approved in South Africa, but several more are on the horizon. Elri Voigt explores the science behind what makes a formulation long-acting and takes a look at some particularly exciting prospects.
That some people are being denied healthcare services because they do not have identity documents or transfer letters is one of the headline findings of community-led clinic monitoring project Ritshidze’s third report on healthcare services in the Eastern Cape. Luvuyo Mehlwana reports.
The latest report published by community-led clinic monitoring group Ritshidze shows that the Free State is the worst-performing province in South Africa when it comes to giving people enough antiretrovirals to last several months at a time. This means people living with HIV in the province have to go collect their medicines more frequently than people in other provinces. Refilwe Mochoari reports.
It is estimated that over 65% of the global HIV burden is in sub-Saharan Africa. Now, in an attempt to propel African voices and perspectives in the next phase of the HIV response in Africa, a group of Africans established an African-led HIV control working group (HCWG). They are all experts from the continent who have come together to develop consensus perspectives on the long-term sustained control of HIV and prioritise the systems and capabilities to achieve it. Drs Yogan Pillay and Izukanji Sikazwe explain the thinking behind the new working group and set out their objectives.
Specially trained and accredited pharmacists in South Africa will now be allowed to dispense medicines to prevent HIV and TB and to treat uncomplicated HIV without a doctor’s script. This is because the North Gauteng High Court this week ruled against an application by a private doctors’ association attempting to block the initiative. Catherine Tomlinson unpacks the judgment and rounds up some responses.
While most male circumcisions performed in the Eastern Cape are done in the traditional manner, there are also significant numbers of medical male circumcisions being conducted. Siyabonga Kamnqa reports on this year’s winter initiation season in the province and the complex interplay between culture, safety, and protection against HIV involved in deciding between the two types of circumcision.
Study findings presented this week at a major HIV conference show that taking a statin every day substantially reduces the chances of suffering a major adverse cardiovascular event in people living with HIV who have a low-to-moderate risk of cardiovascular disease. The findings were also published in the New England Journal of Medicine. Elri Voigt unpacks the study findings and asks what it might mean for people in South Africa.
HIV in South Africa is not the crisis it was 20 years ago, and the country faces a growing burden of non-communicable diseases, but specific investments in HIV nevertheless continue to offer excellent value for money for governments and donors alike. As people gather for the 2023 International AIDS Society Conference in Brisbane, Australia, Marcus Low argues that while funding for HIV interventions remains absolutely essential, it is also critical for the future of the HIV response and people living with HIV that HIV should now be better integrated with other healthcare services, especially those for diabetes and hypertension.
In what is likely one of the largest treatment rollouts in South African history, well over four million people living with HIV have started taking the antiretroviral dolutegravir since its introduction around four years ago. Now, according to a recent study published in the Lancet medical journal, use of dolutegravir in South Africa is associated with more people staying on treatment and higher rates of viral suppression. Elri Voigt unpacks the study findings and assesses progress in the country’s switch to dolutegravir-based HIV treatment.
The 11th SA AIDS conference, recently held in Durban, highlighted the worrying fact that key HIV numbers such as treatment coverage are much lower in children than in adults. But as Elri Voigt reports, conference delegates also heard about new treatments and guidelines that will make life easier for kids and the exciting potential of several new long-acting experimental treatments.
June is Men’s Health Month and while the focus is on men’s attitudes about their health, we have also been reflecting on the health sector’s attitudes about men. Men are not indifferent about their health and they are not inherently poor health-seekers. If many of them are avoiding healthcare services, let’s consider that it may be because they are not getting what they need from the healthcare system, writes Shawn Malone.